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Abstract This multicenter phase II study conducted by
the Spanish Neuro-Oncology Group evaluated the activity
of an extended, dose-dense temozolomide regimen in
patients with temozolomide-refractory malignant glioma.
Adult patients (at least 18 years of age) with WHO grade
III or IV glioma and a Karnofsky Performance Status of 60
or higher were treated with temozolomide (85 mg/m
2/day)
for 21 consecutive days every 28-day cycle until disease
progression or unacceptable toxicity. All patients had
developed progressive disease either during or less than
3 months after completing previous temozolomide treat-
ment. Forty-seven patients were treated with a median of 2
(range, 1–13) cycles of temozolomide. Before study entry,
patients had received a median of 6 cycles of temozolo-
mide: 39 (83%) as part of initial therapy and 23 (49%) as
second-line therapy. Three patients (6.4%) had a partial
response with durations of 8.0, 3.5, and 3.2 months; 15
patients (31.9%) had stable disease with a median duration
of 2.1 months, including 2 patients with stable disease (SD)
for greater than 6 months (14 and 16 months). Median time
to progression was 2 months, and median overall survival
from study entry was 5.1 months. The 6-month progres-
sion-free survival rate was 16.7%. The most common
hematologic toxicities were lymphopenia, thrombocytope-
nia, and leukopenia. Lymphopenia occurred in 83% of
patients and was grade 3 in 28%, but no opportunistic
infections occurred. In conclusion, this extended dose-
dense schedule of temozolomide appears to have modest
activity in patients refractory to previous treatment with
temozolomide and is associated with manageable toxicity.
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Malignant gliomas are aggressive tumors and, despite
recent improvements in their treatment, almost always
relapse after ﬁrst-line treatment and remain incurable [1].
The majority of patients with high-grade gliomas receive
temozolomide either as ﬁrst-line treatment in combination
with radiotherapy or at relapse, based on evidence from
prospective trials demonstrating the clinical beneﬁt of
temozolomide in these settings [2, 3]. Temozolomide is an
imidazotetrazine derivative that methylates the DNA at
several sites including N
7-guanine (70%), N
3-adenine (9%),
or O
6-guanine (5%) [4]. However, only methylation at
O
6-guanine and O
6-methylguanine DNA adducts appears to
drive the cytotoxic activity of temozolomide [4, 5].
TheDNAdamagecausedbytemozolomideisrepairedby
O
6-methylguanine methyltransferase (MGMT), which is
consumed in the process [6]. Several studies have suggested
that resistance to alkylating agents is primarily mediated by
MGMT [6–8]. Furthermore, it has been demonstrated that
temozolomide decreases MGMT activity in peripheral
mononuclear cells in a schedule-dependent manner [9], and
that protracted administration of temozolomide results in
more extensive and sustained depletion of MGMT [10].
Finally, it has been demonstrated that depletion of MGMT
enhances the cytotoxicity of temozolomide and other
alkylating agents [11].
Based on these observations, it is reasonable to hypoth-
esize that extended temozolomide administration may
overcome resistance through MGMT depletion and restore
sensitivity to temozolomide in patients with temozolomide-
refractory malignant glioma. The present trial was designed
bytheSpanishNeuro-OncologyGroup(GENOM)totestthe
activity of an extended, dose-dense temozolomide regimen
(85 mg/m
2 9 21 days every 28 days) in patients who had
progressed following ﬁrst-line or second-line treatmentwith
temozolomide. This dose was selected based on the results
of a phase I trial in patients previously treated with tem-
ozolomide [12].
Patients and methods
Patient eligibility
Adult patients (at least 18 years of age) with histologically
conﬁrmed, temozolomide-refractory, WHO grade III or IV
glioma and a Karnofsky Performance Status (KPS) of 60
or higher were included. Patients were eligible and consid-
ered refractory to temozolomide if they developed pro-
gressive disease during temozolomide treatment or less
than 3 months after completing previous temozolomide
treatment.
Adequate laboratory values were required as follows:
absolute neutrophil count C1,500/ll, platelet count
C100,000/ll, hemoglobin greater than 10 g/dl or 100 g/l,
blood urea nitrogen and serum creatinine less than 1.5 times
the upper limit of laboratory normal, total and direct serum
bilirubin less than 1.5 times the upper limit of laboratory
normal, aspartate aminotransferase or alanine aminotrans-
ferase less than 3 times the upper limit of laboratory normal,
and alkaline phosphatase less than 2 times the upper limit of
laboratory normal. Patients were required to have been on a
non-increasing corticosteroid dose for C72 h before base-
line neuroimaging and study drug administration, and to
have a life expectancy greater than 12 weeks. All patients
were required to provide written informed consent.
Study design
This was a multicenter phase II trial conducted by the GE-
NOM. Institutional review boards at each study center
approved the study. The primary objective was to assess
whether an extended temozolomide dosing schedule can
overcome tumor resistance to the drug. Secondary objec-
tives were response and tolerability. According to the
2-stagemodelofSimonetal.[13],theprimaryobjectivewas
considered not reached if no objective response was
observed in the ﬁrst 10 patients or if less than 3 responses
were observed among 29 patients in the second stage.
Sample size was estimated according to the Simon 2-stage
phaseIIdesign(P0 = 5%responserate;P1 = 20%response
rate) [13]. To achieve an (a, b) error of (0.05, 0.2), a total of
29 patients were required, and to achieve an (a, b) error of
(0.05, 0.1), a total of 43 patients were required.
Treatment
After a 4-week clearance period to allow recovery from
toxicities, patients received temozolomide at a starting dose
of 85 mg/m
2/day in a fasting state for 21 consecutive days
every 28-day cycle. Temozolomide treatment was admin-
istered until disease progression (PD) or unacceptable tox-
icity occurred. Three dose levels were deﬁned: 85 mg/m
2,
75 mg/m
2, and 65 mg/m
2. If neutrophils were over 1500/ll
and platelets over 100,000/ll patients were treated at the
85 mg/m
2 dose; otherwise, treatment was delayed for
1 week to a maximum of 3 weeks until recovery. If neu-
trophils were below 500/ll for 5 days, or platelets were
below 25,000/ll, or if the treatment delay was greater than
2 weeks, the dose was reduced to the next lower level. If
nonhematologic toxicity of grade 3 or greater occurred, the
dose was also reduced. Prophylactic antiemetic therapy
with metoclopramide or 5-HT antagonist was administered
to all patients. No Pneumocystis jirovecii pneumonia pro-
phylaxis was administered.
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123Assessment of response and safety
Response was assessed according to Macdonald’s criteria
[14]. Neurologic examination and steroid dose modiﬁca-
tion were recorded at each cycle. Neuroimaging with
gadolinium-enhanced MRI was performed at least every 2
cycles or if PD was suspected based on neurologic symp-
toms. Complete response was deﬁned as complete disap-
pearance of all detectable tumors as determined by 2
gadolinium-enhanced MRI scans of the brain performed
not less than 4 weeks apart. Adverse events were graded
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events v3.0.
Results
A total of 47 patients were enrolled and received at least 1
cycle of temozolomide. All patients were assessable for
response and safety. Baseline patient characteristics are
shown in Table 1. Median time from the diagnosis to study
entry was 14 months (range 6–126 months). Before study
entry, patients had received a median of 6 (range 1–21)
cycles of temozolomide: 39 patients (83%) as part of initial
therapy and 23 patients (49%) as second-line therapy.
Thus, some patients had received temozolomide as part of
both ﬁrst- and second-line therapy. All patients had
progressed during or within 3 months of completing stan-
dard-dose therapy and at least 6 months after completing
chemoradiotherapy. No patients received dose-dense tem-
ozolomide before study entry. Anticonvulsant therapy was
administered to 31 patients (66%). The most frequently
used anticonvulsants were phenytoin in 17 patients (55%),
valproic acid in 11 patients (36%), gabapentin in 6 patients
(19%), and levetiracetam in 5 patients (16%). Some
patients received more than 1 anticonvulsant drug.
Patients received a median of 2 (range, 1–13) cycles of
temozolomide on study, and a total of 168 treatment cycles
were administered. Sixteen cycles were delayed in 7
patients as a result of hematologic toxicity in 3 patients,
nonhematologic toxicity in 2 patients, and for administra-
tive reasons in 2 patients. Only 3 cycles were dose reduced
in 2 patients because of hematologic toxicity.
Among 47 treated patients, 3 (6.4%) had a partial
response (95% conﬁdence interval [CI]: 0.6%, 13.2%),
including 1 patient with oligodendroglioma who had
received 3 previous lines of therapy, 1 patient with a
glioblastoma who had received 2 previous lines of therapy,
and 1 patient with a glioblastoma who had received 1
previous line of therapy. Duration of the responses was 8,
3.2, and 3.5 months, respectively. In addition, 15 patients
(31.9%) had stable disease (SD). Median duration of SD
was 2.1 months, and 2 patients remained stable for greater
than 6 months (14 and 16 months). One of 3 responders, 6
of 15 patients with SD, and 9 of 30 patients with PD on
study had a response or SD lasting greater than 6 months
during previous temozolomide therapy. All 3 patients who
had a response or SD lasting greater than 6 months on
study also had a response or SD lasting greater than
6 months during previous temozolomide therapy.
At a median follow up of 3.6 months, median time to
progression was 2 months (95% CI: 1.6, 2.4 months;
Fig. 1) and median overall survival from study entry was
5.1 months (95% CI: 3.7, 6.5 months; Fig. 2). The 6-
month progression-free survival (PFS) rates were 16.7%
for the overall population, 0% among patients with glio-
blastoma, and 37.5% among patients with anaplastic
astrocytoma or oligodendroglioma. The 6-month overall
survival rate was 41.6% (95% CI: 25.1%, 58.1%).
The most common hematologic toxicities were lympho-
penia, thrombocytopenia, and leukopenia (Table 2). Lym-
phopenia occurred in 83% of patients and was grade 3 in
28%, but no opportunistic infections occurred. The most
common nonhematologic adverse events or laboratory
Table 1 Patient demographics and baseline clinical characteristics
(N = 47)
Mean age, years (range) 50 (20–77)
Sex, n (%)
Male 33 (70)
Female 14 (30)
ECOG performance status, n (%)
0 8 (17)
1 20 (43)
2 19 (40)
Tumor histology, n (%)
Glioblastoma 27 (57)
Anaplastic astrocytoma 15 (32)
Anaplastic oligodendroglioma 3 (6)
Other 2 (4)
Prior surgery, n (%)
Biopsy only 9 (19)
Partial resection 20 (43)
Gross total resection 17 (36)
Biopsy and partial resection 1 (2)
Prior ﬁrst-line chemotherapy, n (%) n = 47
Temozolomide 38 (81)
Carmustine 4 (9)
PCV 4 (9)
Temozolomide ? cisplatin 1 (2)
Prior second-line chemotherapy, n (%) n = 23
Temozolomide monotherapy 21
Temozolomide-based polychemotherapy 2
ECOG Eastern Cooperative Oncology Group; PCV procarbazine,
lomustine, and vincristine
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123abnormalities were nausea/vomiting, asthenia, and mild
asymptomatic transaminitis (Table 3). Most nonhemato-
logic adverse events and laboratory abnormalities were mild
to moderate in severity, and there was no grade 4 toxicity.
Discussion
Since the publication of the pivotal phase III trial in 2005
demonstrating the superiority of combining radiotherapy
with temozolomide compared with radiotherapy alone in
newly diagnosed glioblastoma patients [8], temozolomide
has become the standard of care for initial treatment of
glioblastoma and is widely used for treatment of anaplastic
glioma. Consequently, standard-dose temozolomide may
no longer be the best treatment option at recurrence. A
variety of options have been explored, including retreat-
ment with temozolomide using a dose-dense schedule or
treatment with nitrosoureas, irinotecan, bevacizumab, or a
variety of novel combinations of these and other agents
[15–19]. Carmustine has demonstrated only limited activity
after temozolomide [18], whereas irinotecan, in combina-
tion with bevacizumab, carmustine, or thalidomide, has
demonstrated promising activity in this setting [15–17, 19].
Presumably most high-grade gliomas are refractory to
alkylating agents at recurrence following initial treatment
with temozolomide. However, a recent report by Perry
et al. [20] of interim data from the RESCUE study has
shown that retreatment with continuous low-dose daily
temozolomide resulted in favorable 6-month PFS rates in
patients who progressed during or after ﬁrst-line temozol-
omide. Other studies have also demonstrated the activity of
dose-dense temozolomide regimens in this setting [21].
The results of the present study have further demon-
strated that retreatment with temozolomide using an
extended, dose-dense schedule can result in objective
responses in patients previously exposed to temozolomide
as part of their initial treatment. Although the observed
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Fig. 1 Kaplan–Meier estimate of time to progression
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Fig. 2 Kaplan–Meier estimate of overall survival
Table 2 Hematologic toxicity by grade
Patients, n (%)
Grade 1 or 2 Grade 3 Total
Lymphopenia 26 (55) 13 (28) 39 (83)
Thrombocytopenia 9 (19) 5 (11) 14 (30)
Leukopenia 13 (28) 1 (2) 14 (30)
Anemia 7 (15) 2 (4) 9 (19)
Neutropenia 8 (17) 1 (2) 9 (19)
Table 3 Most common nonhematologic adverse events and labora-
tory abnormalities by grade
Patients, n (%)
Grade 1 or 2 Grade 3 Total
Adverse events
Nausea/vomiting 12 (26) 1 (2) 13 (28)
Asthenia 8 (17) – 8 (17)
Diarrhea 5 (11) – 5 (11)
Constipation 2 (4) – 2 (4)
Mucositis 2 (4) 1 (2) 3 (6)
Laboratory abnormalities
GPT 24 (51) – 24 (51)
GOT 9 (19) – 9 (19)
Creatinine 6 (13) – 6 (13)
GGT – 1 (2) 1 (2)
Bilirubin 1 (2) – 1 (2
GPT glutamic-pyruvic transaminase, GOT glutamic-oxaloacetic
transaminase, GGT gamma-glutamyl transferase
420 J Neurooncol (2010) 96:417–422
1236.3% partial response rate and 6-month PFS rate were
modest, patients enrolled in this study were pretreated with
a median of 6 cycles of temozolomide, and many patients
received extended treatment with up to 21 cycles of stan-
dard-dose temozolomide before study entry. Similarly,
among patients enrolled in the RESCUE study, those who
received prolonged maintenance therapy with standard-
dose temozolomide (beyond 6 cycles) had a low 6-month
PFS rate (9.5%) [20]. In addition, all patients entered the
present study at least 6 months after completing previous
radiotherapy. This suggests that the responses observed in
the present study were not an artifact of pseudoprogression,
but this cannot be completely ruled out.
It has been observed that patients who have prolonged
SD after primary temozolomide treatment often have a
prolonged response to retreatment with temozolomide [22,
23]. Consistent with these published reports, all patients
who had a durable response or SD in the present study had
previously had a durable response or SD to ﬁrst- or second-
line temozolomide. It should be noted, however, that
objective responses and SD have been observed in patients
who had a short duration of response to ﬁrst-line tem-
ozolomide. Therefore, no patient should be excluded from
retreatment with an extended temozolomide regimen based
on the quality of their response to ﬁrst-line temozolomide.
Compared with the standard 5-day dosing schedule every
28-day cycle, the extended dose-dense schedules result in
approximately a 2-fold greater exposure to temozolomide
and may have greater potential to deplete MGMT activity
within tumor cells and overcome resistance [11]. The ﬁrst
report of an extended temozolomide regimen investigated a
dose of 75 mg/m
2/day for 6 or 7 consecutive weeks [24].
This schedule resulted in a 41% response rate among 17
patients with recurrent glioma. Subsequent studies in glio-
blastoma investigating 2 different extended temozolomide
schedules (7 consecutive days every 2 weeks, or 21 con-
secutive days every 28 days) showed that both schedules
resulted in a signiﬁcant and prolonged depletion of MGMT
in peripheral blood mononuclear cells, which led to the
hypothesis that these dose-dense regimens could potentially
enhance antitumor activity [10]. Two phase II trials in
patients with recurrent glioblastoma also demonstrated that
these regimens are highly active [23, 25]. In the ﬁrst study
conducted in temozolomide-naive patients, the 21-day
continuous schedule resulted in a 9% response rate and a 6-
month PFS rate of 30% [25]. In the second study, the
majority of patients had not been previously exposed to
temozolomide, and the alternating weekly regimen resulted
in a response rate of 15% and a 6-month PFS rate of 44%
[23]. Therefore, the fact that 2 of 27 (7%) glioblastoma
patients in the present study who were previously treated
with temozolomide had an objective response supports the
hypothesis that this dose-dense regimen may overcome
resistance. One limitation of the present study is the lack of
data on MGMT methylation status of these tumors. How-
ever, MGMT methylation status at initial diagnosis has
limited value in the recurrent setting, particularly given the
observation that methylation patterns within the tumor can
change from initial diagnosis to recurrence.
Toxicity associated with extended, dose-dense tem-
ozolomide schedules has been reported to be greater than
that associated with the conventional 5-day schedule and to
consist mainly of lymphopenia [23, 25–28]. In the present
study, grade 3 or higher lymphopenia occurred in nearly
30% of patients. However, no complications related to
immunodeﬁciency such as Pneumocystis jirovecii pneu-
monia were reported, even in the absence of PCP pro-
phylaxis. All toxicities were manageable, and few patients
required treatment delays or dose reductions.
In conclusion, this extended dose-dense schedule of
temozolomide appears to have activity, albeit modest, in
patients who have failed previous treatment with tem-
ozolomide and is associated with manageable toxicity.
These results suggest that extended schedules of temozol-
omide may be preferable to the standard temozolomide
regimen and should be further evaluated in larger ran-
domized studies with prospective stratiﬁcation of patients
by primary tumor type and extent of prior temozolomide
therapy. The full results of the RESCUE study are eagerly
awaited and may provide further insight regarding how
best to use temozolomide in the recurrent setting.
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